Adding Roche's immunotherapy Tecentriq to older drugs doubled the percentage of lung cancer patients who survived a year without their disease advancing, an outcome some experts labeled unprecedented. Roche's November announcement that its Impower 150 trial had broadly succeeded in first-line lung cancer patients helped spur a one-day, $12 billion rally in the Basel-based drugmaker's market capitalization. Roche Chief Executive Severin Schwan sees an opportunity to leap-frog ahead as competitors still await their own lung cancer combination trial results. Patients getting Roche's immunotherapy survived an average of 8.3 months without their disease getting worse, compared with a PFS of 6.8 months for those getting chemotherapy and Avastin. Tecentriq is already approved in bladder cancer treatment and for lung cancer patients who have failed chemotherapy.